MacuSight was founded by Frazier Healthcare Ventures to exploit the potential of rapamycin to treat age-related macular degeneration.
32980 Alvarado-Niles Road
Suite 846
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
